Source:http://linkedlifedata.com/resource/pubmed/id/14551148
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2004-2-3
|
| pubmed:abstractText |
Significant engraftment variability occurs among patients following nonmyeloablative hematopoietic cell transplantation. We analyzed the impact of multiple factors on donor myeloid and T-cell engraftment in 36 patients with metastatic tumors undergoing cyclophosphamide/fludarabine-based conditioning. Higher CD34(+) doses facilitated donor myeloid engraftment, while prior chemotherapy exposure facilitated both donor myeloid and T-cell engraftment. At day 30, median donor T-cell and myeloid chimerism was 98% and 76%, respectively, in those patients with prior chemotherapy versus 88% (P =.008) and 26% (P <.0001) in chemotherapy-naive patients. Donor myeloid chimerism at day 45 was predicted by prior chemotherapy exposure and the log(10) of the CD34(+) dose (adjusted coefficient of determination [R(2)] =.47; P <.0001), while chemotherapy alone impacted donor T-cell engraftment. Patients with prior chemotherapy were more likely to develop acute grades II to IV graft-versus-host disease (GVHD; 8/18) compared with chemotherapy-naive patients (2/18; P =.031). Thus, tailoring the intensity of nonmyeloablative conditioning based on prior chemotherapy exposure is an important consideration in trial design.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0006-4971
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
103
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1560-3
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:14551148-Adult,
pubmed-meshheading:14551148-Aged,
pubmed-meshheading:14551148-Antigens, CD34,
pubmed-meshheading:14551148-Antineoplastic Agents,
pubmed-meshheading:14551148-Blood Platelets,
pubmed-meshheading:14551148-Combined Modality Therapy,
pubmed-meshheading:14551148-Female,
pubmed-meshheading:14551148-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:14551148-Hematopoietic Stem Cells,
pubmed-meshheading:14551148-Humans,
pubmed-meshheading:14551148-Male,
pubmed-meshheading:14551148-Middle Aged,
pubmed-meshheading:14551148-Neoplasms,
pubmed-meshheading:14551148-Neutrophils,
pubmed-meshheading:14551148-Regression Analysis,
pubmed-meshheading:14551148-T-Lymphocytes,
pubmed-meshheading:14551148-Transplantation, Homologous,
pubmed-meshheading:14551148-Transplantation Chimera,
pubmed-meshheading:14551148-Transplantation Conditioning
|
| pubmed:year |
2004
|
| pubmed:articleTitle |
Prior chemotherapy and allograft CD34+ dose impact donor engraftment following nonmyeloablative allogeneic stem cell transplantation in patients with solid tumors.
|
| pubmed:affiliation |
Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1652, USA.
|
| pubmed:publicationType |
Journal Article
|